Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced the launch of a new sub-brand, RenBiologics, to represent its antibody discovery business division. The RenBiologics business will focus on out-licensing and co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice, Biocytogen’s fully human antibody/TCR discovery platforms.
Biocytogen’s fully human antibody sequences are generated by proprietary RenMice strains, each engineered to lack specific drug target genes. From March 2020 to the third quarter of 2023, Biocytogen’s large-scale therapeutic antibody R&D initiative, Project Integrum, completed over 900 target antibody discovery projects, with more than 40 in the Preclinical Candidate (PCC) to Investigational New Drug (IND) stages. This effort has resulted in an extensive antibody library of over 400,000 sequences available for evaluation and out-licensing to pharmaceutical and biotechnology companies.
RenMice-derived fully human antibodies have the potential to be developed into novel therapies for a wide range of diseases, including various cancers, inflammatory and autoimmune diseases, infectious diseases, metabolic diseases, cardiovascular diseases, and neurological diseases.- Flcube.com
